Navigation Links
Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced the initiation of a proof-of-concept clinical trial of SLC022 in patients with post-herpetic neuralgia (PHN). PHN, a painful complication of shingles, affects approximately 200,000 people a year in the US alone. The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness of SLC022 in controlling pain associated with PHN. Solace anticipates having results from the study in the second half of 2009.

SLC022 is an orally administered glial cell modulator that has shown efficacy in well-established preclinical pain models. Glial cells represent an important new target for the treatment of chronic pain based on their active role in neuronal pain signaling.

"The initiation of this study is another important milestone for Solace in our drive to discover and develop innovative treatments for pain," said Dr. Eliot Forster, Solace's Chief Executive Officer. "Our confidence in SLC022 is underpinned by a large body of prior preclinical and clinical data generated during the compound's previous development in a non-pain indication. We believe these data lower the development risk and enhance the opportunity for a favorable clinical profile."

Solace's advancement of SLC022 caps a year of significant progress. In 2008, Solace expanded its glial cell modulator program by identifying next-generation, novel leads with attractive drug properties. The company made equally rapid progress in optimizing inhibitors of the enzyme GTP cyclohydrolase 1 (GCH1), a key target within the BH4 synthesis pathway, and in identifying additional promising drug targets.

Solace Pharmaceuticals also established a two-year collaboration with Professor Keith Channon, MD FRCP, of the Department of Cardiovascular Medicine at the University of Oxford, UK. Professor Channon is a world-leading expert in the biochemistry of the BH4 pathway and the vascular endothelial system. Dr. Channon's work complements Solace's work in the development of small-molecule inhibitors of the BH4 pathway for treating chronic pain.

"We believe that the collaboration between Professor Channon and Solace will significantly augment the understanding of GCH1 and help advance development of promising therapeutic compounds," said Dr. Al Naylor, Solace's Head of Research.

About Solace Pharmaceuticals

Solace Pharmaceuticals discovers and develops innovative treatments for pain. Solace's research and development programs are focused on exploiting novel biological understanding of disease targets that play a role in the pathogenesis of pain and that have disease-modifying potential in two key areas: modulating the activity of glial cells and intervening in the tetrohydrobiopterin (BH4) pathway. SLC022, the company's lead drug candidate, is in phase II clinical development in patients with post-herpetic neuralgia (PHN). Solace's research and development are supported by a strong and expanding intellectual property portfolio. For more information, please visit the company's website at http://www.solacepharma.com.

     Contact:

     Marie Lossky, PhD
     Director, Business Development and
     Intellectual Property
     Solace Pharmaceuticals
     Phone: 617 401 4006
     Email: mlossky@solacepharma.com

'/>"/>
SOURCE Solace Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
2. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
8. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
9. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
10. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Switzerland , April 27, 2016 ... AG announced the launch of a Phase 2 clinical ... residual hearing in patients undergoing cochlear implantation (CI) surgery. ... recruiting patients in Germany and ... into the middle ear at the time of surgery. ...
(Date:4/26/2016)... 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... at the Deutsche Bank 41 st Annual Health Care ... You are invited to listen to the live ... access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay ... of the live event and accessible at the links above ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... The ... , a program to critically evaluate and rank health-focused applications and connected devices ... to provide independent, unbiased and accurate information to help accelerate patient and provider ...
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... Orlando-based Maximized ... as they go for gold in Rio. Under the care of Maximized Living ... golds! , In an unprecedented showing, Maximized Living is sending the largest contingent of ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... notified by the Accreditation Council for Graduate Medical Education (ACGME) that it has ... This is the first accreditation of three residency programs that Memorial is currently ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... ... 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing in ... physicians has been invited to be a featured speaker at the Texas Society of ... April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation ...
Breaking Medicine News(10 mins):